Floatz logo

BOTULINUM B TOXIN

Brain Injury

Georgetown Universityprotein_peptidePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Brain Injury cohort.

Asset / SponsorPhaseRating
Apsolol
Hamad Medical Corporation
Phase 4BB
Tranexamic Acid
Daniel Nishijima, MD, MAS
Phase 3BB
TESTOSTERONE UNDECYLATE
Craig Hospital
Phase 4BB
Enoxaparin
Hennepin Healthcare Research Institute
Phase 4BB
Methylphenidate
Dartmouth-Hitchcock Medical Center
Phase 4BB

View all 48 →

Same molecule, other indications

BOTULINUM B TOXIN is also rated in:

stroke disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →
neoplasmDormant
B
Indicative · Phase 4
61 / 100
View asset →
cerebral palsyActive
CCC
Indicative · Phase 2/3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →